Author name: hayatpharma

eCTD Submission Format: 10 Common Mistakes That Cause Technical Rejections in 2026 eCTD Submission Format: 10 Common Mistakes That Cause Technical Rejections in 2026 By the regulatory team at Hayat Pharmaceuticals Consulting (HPC) A pharmaceutical dossier can be scientifically perfect and still fail. Not during review, but before review even begins. In the electronic submission […]

GMP Compliance · FDA Inspection Readiness · 2026 6 GMP Compliance Gaps Regulators Always Find — And How to Close Them Before Your Next Inspection In 2026, over 60% of critical inspection findings trace back to weak pharmaceutical quality systems, not the product. Here is what FDA inspectors look for, and how to stay ahead

Process Validation in 2026: Meeting FDA and EMA Expectations “Process validation is not a one-time event. It is a lifecycle commitment that links science, risk management, and regulatory compliance from Day 1 through commercial manufacture.” In 2026, pharmaceutical manufacturers face a regulatory environment that is more data-driven, more transparent, and more demanding than ever before.

How Hayat Pharmaceuticals Consulting Helps Biotech Startups Building a biotech startup is one of the most ambitious things a scientist or entrepreneur can do. You have a molecule with potential. You have a vision for how it could change patients’ lives. But between that vision and a commercially approved drug lies one of the most

Integrated Analytical and Stability Solutions for Product Development The journey of transforming a pharmaceutical compound from discovery to commercial production is one of the most difficult processes in the life sciences sector. Although early-stage discoveries frequently show encouraging biological activity, converting these compounds into stable, manufacturable and legally compliant products necessitates a strong analytical and stability approach.

Advancing Pharmaceutical Formulation Development The formulation of pharmaceutical drugs is a crucial step for identifying the appropriate dosage form, composition and production method in the drug development process. A drug may fail phase I clinical trials prior to effective absorption, if it cannot be administered in a stable form and limiting its market potential. In

Process Chemistry Excellence: From Discovery to Commercialization In pharmaceutical development process, finding a promising drug candidate is only the beginning of the journey. The true difficulty is turning that drug into a powerful, scalable, regulatory compliant medicine that is prepared for commercial success. From inefficient synthetic paths and uncontrolled impurity profiles to unstable solid forms